120 related articles for article (PubMed ID: 23998443)
1. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma.
Wong HK
Discov Med; 2013 Sep; 16(87):71-8. PubMed ID: 23998443
[TBL] [Abstract][Full Text] [Related]
2. Deciphering Tumor Cell Evolution in Cutaneous T-Cell Lymphomas: Distinct Differentiation Trajectories in Mycosis Fungoides and Sézary Syndrome.
Jiang TT; Cao S; Kruglov O; Virmani A; Geskin LJ; Falo LD; Akilov OE
J Invest Dermatol; 2024 May; 144(5):1088-1098. PubMed ID: 38036289
[TBL] [Abstract][Full Text] [Related]
3. CD164 identifies CD4
Benoit BM; Jariwala N; O'Connor G; Oetjen LK; Whelan TM; Werth A; Troxel AB; Sicard H; Zhu L; Miller C; Takeshita J; McVicar DW; Kim BS; Rook AH; Wysocka M
Arch Dermatol Res; 2017 Jan; 309(1):11-19. PubMed ID: 27766406
[TBL] [Abstract][Full Text] [Related]
4. Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma.
Ion A; Popa IM; Papagheorghe LM; Lisievici C; Lupu M; Voiculescu V; Caruntu C; Boda D
Dis Markers; 2016; 2016():9602472. PubMed ID: 27821903
[TBL] [Abstract][Full Text] [Related]
5. The Role of Cytokines in Cutaneous T Cell Lymphoma: A Focus on the State of the Art and Possible Therapeutic Targets.
Guglielmo A; Zengarini C; Agostinelli C; Motta G; Sabattini E; Pileri A
Cells; 2024 Mar; 13(7):. PubMed ID: 38607023
[TBL] [Abstract][Full Text] [Related]
6. Single-cell analysis of Sézary syndrome reveals novel markers and shifting gene profiles associated with treatment.
Borcherding N; Severson KJ; Henderson N; Ortolan LS; Rosenthal AC; Bellizzi AM; Liu V; Link BK; Mangold AR; Jabbari A
Blood Adv; 2023 Feb; 7(3):321-335. PubMed ID: 35390145
[TBL] [Abstract][Full Text] [Related]
7. Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials.
Lai P; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):34-51. PubMed ID: 33628583
[TBL] [Abstract][Full Text] [Related]
8. The cross-talk between miRNAs and JAK/STAT pathway in cutaneous T cell lymphoma: Emphasis on therapeutic opportunities.
Patil K; Sher G; Kuttikrishnan S; Moton S; Alam M; Buddenkotte J; Ahmad A; Steinhoff M; Uddin S
Semin Cell Dev Biol; 2024 Feb; 154(Pt C):239-249. PubMed ID: 36216715
[TBL] [Abstract][Full Text] [Related]
9. Unraveling the Mechanisms of PD-1 Regulation in Sézary Syndrome: Epigenetic Regulation as Potential Mechanism?
Querfeld C
J Invest Dermatol; 2023 Dec; 143(12):2338-2339. PubMed ID: 37610396
[No Abstract] [Full Text] [Related]
10. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
11. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in primary cutaneous T-cell lymphoma.
DeSimone JA; Sodha P; Ignatova D; Dummer R; Cozzio A; Guenova E
Curr Opin Oncol; 2015 Mar; 27(2):128-33. PubMed ID: 25594623
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma.
Sandoval J; Díaz-Lagares A; Salgado R; Servitje O; Climent F; Ortiz-Romero PL; Pérez-Ferriols A; Garcia-Muret MP; Estrach T; Garcia M; Nonell L; Esteller M; Pujol RM; Espinet B; Gallardo F
J Invest Dermatol; 2015 Apr; 135(4):1128-1137. PubMed ID: 25405321
[TBL] [Abstract][Full Text] [Related]
14. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
Hughes CF; Newland K; McCormack C; Lade S; Prince HM
Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
[TBL] [Abstract][Full Text] [Related]
15. Relative frequency and survival of primary cutaneous lymphomas: a retrospective analysis of 98 patients.
Liu J; Yu X; Liu Y; Jin H; Ma D; Qu T; Wang T; Sun Q
Chin Med J (Engl); 2014; 127(4):645-50. PubMed ID: 24534216
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
[TBL] [Abstract][Full Text] [Related]
17. Primary cutaneous lymphomas: single center experience of dermatology and hematology clinics.
Payzin B; Ogretmen Z; Cidem Yildirim A; Ozturk Durur S; Sentekin S
J BUON; 2014; 19(1):171-7. PubMed ID: 24659660
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous lymphomas: an update. Part 1: T-cell and natural killer/t-cell lymphomas and related conditions.
Kempf W; Kazakov DV; Kerl K
Am J Dermatopathol; 2014 Feb; 36(2):105-23. PubMed ID: 24556897
[TBL] [Abstract][Full Text] [Related]
19. Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach.
Al Hothali GI
Int J Health Sci (Qassim); 2013 Jun; 7(2):220-39. PubMed ID: 24421750
[TBL] [Abstract][Full Text] [Related]
20. Novel therapies for cutaneous T-cell lymphoma: what does the future hold?
Guenova E; Hoetzenecker W; Rozati S; Levesque MP; Dummer R; Cozzio A
Expert Opin Investig Drugs; 2014 Apr; 23(4):457-67. PubMed ID: 24397291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
